Jianjiong Gao
Auto-generated profile, based on publicly available information

Jianjiong Gao

Caris Life Sciences, Phoenix, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ECEthan Cerami
Ethan Cerami
JGJianjiong Gao
Jianjiong Gao
UDUgur Dogrusoz
Ugur Dogrusoz
BGBenjamin E. Gross
Benjamin E. Gross
SSSelcuk Onur Sumer
Selcuk Onur Sumer
NSNikolaus Schultz
Nikolaus Schultz
The cBio Cancer Genomics Portal (http://cbioportal.org) is an open-access resource for interactive exploration of multidimensional cancer genomics data sets, currently providing access to data from more than 5,000 tumor samples from 20 cancer studies. The cBio Cancer Genomics Portal significantly lowers the barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers researchers to translate these rich data sets into biologic insights and clinical applications. Cancer Discov; 2(5); 401–4. ©2012 AACR.

2 April 2013 in Science Signaling
Verified
Journal Article
Open access
PDF file
JGJianjiong Gao
Jianjiong Gao
BABülent Arman Aksoy
Bülent Arman Aksoy
UDUgur Dogrusoz
Ugur Dogrusoz
GDGideon Dresdner
Gideon Dresdner
BGBenjamin Gross
Benjamin Gross
NSNikolaus Schultz
Nikolaus Schultz
The cBioPortal enables integration, visualization, and analysis of multidimensional cancer genomic and clinical data.

1 October 2013 in Cell
Verified
Journal Article
Closed access
CBCameron W. Brennan
Cameron W. Brennan
RVRoel G.W. Verhaak
Roel G.W. Verhaak
AMAaron McKenna
Aaron McKenna
BCBenito Campos
Benito Campos
HNHoutan Noushmehr
Houtan Noushmehr
RMRoger McLendon
Roger McLendon

1 April 2018 in Cell
Verified
Journal Article
Open access
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
MMMarco Mina
Marco Mina
JAJoshua Armenia
Joshua Armenia
WCWalid K. Chatila
Walid K. Chatila
ALAugustin Luna
Augustin Luna
AMArmaz Mariamidze
Armaz Mariamidze
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tumor types. Using mutations, copy-number changes, mRNA expression, gene fusions and DNA methylation in 9,125 tumors profiled by The Cancer Genome Atlas (TCGA), we analyzed the mechanisms and patterns of somatic alterations in ten canonical pathways: cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53 and β-catenin/Wnt. We charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity. Eighty-nine percent of tumors had at least one driver alteration in these pathways, and 57% percent of tumors had at least one alteration potentially targetable by currently available drugs. Thirty percent of tumors had multiple targetable alterations, indicating opportunities for combination therapy.

8 May 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AZAhmet Zehir
Ahmet Zehir
RBRyma Benayed
Ryma Benayed
Ronak ShahRonak Shah
Ronak Shah
ASAijazuddin Syed
Aijazuddin Syed
SMSumit Middha
Sumit Middha
MBMichael F Berger
Michael F Berger
MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inform patient enrollment in genomically matched clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC). Sequencing results of tumor and matched normal tissue from a cohort of >10,000 patients with detailed clinical annotation provide an overview of the genomic landscape of advanced solid cancers and bring new insights into molecularly guided cancer therapy. Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.

1 May 2015 in Cell
Verified
Journal Article
Closed access
DRDan Robinson
Dan Robinson
EAEliezer M. Van Allen
Eliezer M. Van Allen
YWYi-Mi Wu
Yi-Mi Wu
NSNikolaus Schultz
Nikolaus Schultz
RLRobert J. Lonigro
Robert J. Lonigro
ACArul M. Chinnaiyan
Arul M. Chinnaiyan